Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00885066

Enrollment

Registered

2009-04-21

Start date

2008-05-01

Completion date

2009-10-01

Last updated

2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

stage III pancreatic cancer, stage IV pancreatic cancer, adenocarcinoma of the pancreas, recurrent pancreatic cancer

Brief summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine given together with capecitabine and erlotinib in treating patients with advanced pancreatic cancer.

Detailed description

OBJECTIVES: Primary * Determine the maximum-tolerated dose of the combination of gemcitabine hydrochloride, capecitabine, and erlotinib hydrochloride in patients with advanced pancreatic cancer. Secondary * Analyze the limiting toxicities according to CTC. * Analyze the toxicity according to CTC. * Determine the recommended dose. * Determine the pharmacokinetic dosages of the three drugs. * Analyze interactions between the drugs. OUTLINE: This is a multicenter study. Patients receive one course of chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, oral capecitabine twice daily on days 1-21, and oral erlotinib hydrochloride once daily on days 1-28.

Interventions

DRUGcapecitabine

DRUGerlotinib hydrochloride

DRUGgemcitabine hydrochloride

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed adenocarcinoma of the pancreas * Advanced disease * No standard curative therapy available * Must have received prior first-line chemotherapy * No brain metastasis PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Life expectancy ≥ 8 weeks * ANC ≥ 1.5 x 10\^9/ L * Platelet count ≥ 130 x 10\^9/ L * Hemoglobin ≥ 10 g/dL * Liver transaminases ≤ 1.5 times upper limit of normal (ULN) (≤ 5 times ULN in the presence of liver metastases) * Bilirubin ≤ 1.5 times ULN * Creatinine ≤ 130 mmol/L OR creatinine clearance \> 30 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No intolerance or hypersensitivity to any of the drugs being tested * No history of interstitial lung disease * No history of severe cardiac disease * No serious uncontrolled infection * No rare hereditary disorders, i.e., galactosemia, lactase deficiency, or malabsorption of glucose or galactose syndrome * Must not be deprived of liberty or under guardianship * Must not be on probation PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior erlotinib hydrochloride * No concurrent potent inducers or inhibitors of cytochrome P450 or CYP3A4 * More than 14 days since participation in another clinical trial

Design outcomes

Primary

Measure	Time frame
Clinical or laboratory toxicities as assessed by CTC	1 year

Countries

France

Contacts

PRINCIPAL_INVESTIGATOREric Francois

Centre Antoine Lacassagne

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026